ITP - immune thrombocytopenia
Clinical trials for ITP - immune thrombocytopenia explained in plain language.
Never miss a new study
Get alerted when new ITP - immune thrombocytopenia trials appear
Sign up with your email to follow new studies for ITP - immune thrombocytopenia, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for teens with rare bleeding disorder: experimental drug enters final testing
Disease control Recruiting nowThis study tests an IV drug called efgartigimod in teens aged 12 to 18 with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet counts…
Matched conditions: ITP - IMMUNE THROMBOCYTOPENIA
Phase 2/3 • Sponsor: argenx • Aim: Disease control
Last updated Sep 21, 2026 16:00 UTC
-
New drug OM336 aims to tame overactive immune system
Disease control Recruiting nowThis early-phase trial tests a new drug called OM336 in 32 adults with autoimmune cytopenias, conditions where the immune system attacks blood cells. The study focuses on safety and how the drug moves through the body, not yet on curing the disease. Participants must have tried a…
Matched conditions: ITP - IMMUNE THROMBOCYTOPENIA
Phase 1 • Sponsor: Lakefront Biotherapeutics West LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Triple-Drug attack tame immune thrombocytopenia?
Disease control Recruiting nowThis trial is testing whether a combination of standard steroids, a platelet-boosting drug (TPO-RA), and targeted antibodies (rituximab or anti-CD38) can improve outcomes for adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys p…
Matched conditions: ITP - IMMUNE THROMBOCYTOPENIA
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Gene-Edited immune cells take on autoimmune blood diseases
Disease control Recruiting nowThis early-stage trial tests a one-time treatment called CTX112, made from donor immune cells edited with CRISPR technology. It aims to safely control two autoimmune diseases where the body attacks its own blood cells: immune thrombocytopenia (ITP) and warm autoimmune hemolytic a…
Matched conditions: ITP - IMMUNE THROMBOCYTOPENIA
Phase 1/2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC